KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

November 13, 2026 updated by: Wuhan KadGeno Biotechnology Co., Ltd

Phase 1/2, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-associated cervical HSIL.

The study consists of three parts: dose escalation, an immunogenicity expansion cohort (Phase 1), and a dose expansion phase (Phase 2). In Phase 1a, 3+3 dose escalation of KDTV001 Injection will be conducted separately for IM and IC administration, with two ascending dose levels evaluated for each route. During the dose-escalation phase, if a dose cohort is assessed as safe by SRC, an immunogenicity expansion of 10-20 participants may be conducted. Based on Phase 1 safety and immunogenicity data, 1-2 dose levels will be selected for Phase 2 dose expansion for both IC and IM. In the Phase 2 dose-expansion phase, each dose cohort will enroll 30-50 participants. Both phases will consist of a screening period, a treatment and safety follow-up period, an end of study visit (EOS) and a long-term follow-up period.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

304

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Hubei
      • Wuhan, Hubei, China
        • Recruiting
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Principal Investigator:
          • Peng Wu, Prof
      • Wuhan, Hubei, China
        • Recruiting
        • TongJi Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contact:
          • Nan Yu, Prof
        • Principal Investigator:
          • Nan Yu, Prof
        • Principal Investigator:
          • Gang Chen, Prof

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Cervical HSIL (defined as CIN 2 or 3), with the histological diagnosis confirmed by central pathology review within 12 weeks before the first study dose. Note: CIN 3 patients for whom immediate lesion removal is recommended by a clinician will not be enrolled in this study.
  • Confirmed cervical infection with HPV types 16, and/or 18, and/or 52 at screening by Central Lab. If there are other high-risk types of HPV infection, the investigator should assess based on the participant's infection history to exclude cases where such non-target types are persistent infections and the primary causes of disease.
  • All participants must have lesions of adequate size to ensure that a visible lesion remains after the screening biopsy.
  • Participants must have satisfactory colposcopy at screening, defined as full visualization of entire lesion and the squamo-columnar junction (Type I or II transformation zone).
  • Female participants aged ≥ 18 years.
  • No significant impairment of major organ functions, including but not limited to hematopoietic, cardiac, pulmonary, hepatic, and renal functions.
  • Female participants must meet one of the following criteria with respect their reproductive capacity:

a Post-menopausal as defined by spontaneous amenorrhea for more than 12 months; b Surgically sterile due to absence of ovaries or due to a bilateral tubal ligation/occlusion performed more than 12 months prior to screening; c Women of Child Bearing Potential (WOCBP) must have a negative serum pregnancy test during the screening period; participants must agree to use reliable contraceptive methods (barrier methods or abstinence) with their partners during the study and for at least 12 months after the last dose of investigational product.

- Be willing to participate in this study and provide a signed informed consent form prior to participating in the trial.

Exclusion Criteria:

  • Cervical adenocarcinoma in situ (AIS), atypical endometrial or glandular cells, or histopathological evidence of invasive cervical carcinoma on cervical biopsy within 12 weeks prior to the first study dose.

  • Have received pelvic radiotherapy within the past five years.

  • Have any active infection requiring systemic anti-infective treatment (routine prophylactic anti-infective treatment per the clinical trial institution is allowed) or an unexplained fever >38.5°C during the screening period.

  • Have more than three episodes of abnormal uterine bleeding within the recent three months.

  • Have a history of receiving adenovirus-based therapies within 6 months.

  • Participants with symptomatic vaginitis, including but not limited to bacterial, fungal, or trichomonal vaginitis. Participants may be eligible for enrollment after satisfactory treatment.

  • Participants who are pregnant, lactating, or unwilling to use protocol-defined contraception at any time during the study;

  • History of other organ systems malignancies within the past five years, which in the investigator's judgment may interfere with study conduct or require systemic anticancer therapy during the study.

  • Poorly controlled diabetes (defined as fasting blood glucose ≥ 10 mmol/L) despite medication at screening.

  • Major surgery within 4 weeks prior to the first dose or anticipated during the study (excluding diagnostic procedures). Participants must have fully recovered from the toxicities and/or complications of the prior major surgery if conducted more than 4 weeks prior to the first study dose.

  • Participants with hereditary bleeding diathesis or coagulopathy, history of thrombosis or hemorrhage, or requirement for chronic anticoagulant therapy.

  • Have a history of severe cardiovascular or cerebrovascular diseases, including but not limited to:

    1. Severe cardiac conduction abnormalities requiring clinical intervention (e.g. ventricular arrhythmias requiring treatment, second- or third-degree atrioventricular block).
    2. QTcF interval ≥ 460 ms on resting 12-lead ECG.
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, cerebrovascular accident, or other Grade 3 or higher cardiovascular events occurring within six months prior to the first study dose.
    4. New York Heart Association (NYHA) functional classification ≥ Class II OR left ventricular ejection fraction (LVEF) <50%, OR other investigator-assessed high-risk structural heart diseases.
    5. Clinically uncontrolled hypertension.
  • Participants with autoimmune disorders or immunodeficiency conditions, or who have received allogeneic hematopoietic stem cell transplantation, or solid organ transplantation.

  • Asplenia, functional asplenia, or any condition resulting in absence or removal of the spleen.

  • Have any of the following serum virology findings:

    1. Positive HIV antibody test; OR

    2. Positive Treponema pallidum antibody; OR

    3. Active hepatitis B infection defined as:

      HBsAg positive AND HBV-DNA >500 IU/mL or above institutional detection limit if higher than standard threshold (only when the lower limit of detection threshold of the clinical trial institution is higher than 500 IU/mL)

    4. Active hepatitis C infection defined as: Anti-HCV positive AND HCV-RNA above institutional detection limit Note: Individuals receiving prophylactic antiviral therapies other than interferon are allowed to be enrolled.

  • Have uncontrolled seizures, central nervous system disorders, or psychiatric conditions resulting in loss of cognitive capacity.

  • Have a history within the past year of, or are currently experiencing, any other clinically significant uncontrolled medical conditions, including but not limited to cardiac, hepatic, pulmonary, renal, gastrointestinal, neurological, psychiatric, metabolic disorders.

  • Have received any blood products within three months prior to enrollment.

  • Require concomitant use of antiviral therapy OR have received antiviral medications within two weeks prior to the first administration of the study drug.

  • Have received any vaccination within four weeks prior to enrollment.

  • History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines are not excluded).

  • Tattoos, scars, or active dermatologic lesions or rashes at the injection site that interfere with local safety assessments.

  • Currently receiving OR have received following doses of systemic corticosteroid therapy prior to the first administration of the investigational product:

    1. Long-term corticosteroid therapy: > 10 mg/day prednisone or equivalent within 30 days prior to the first study dose;
    2. Short-term corticosteroid therapy: ≥ 1 mg/kg/day prednisone or equivalent for ≥ 2 courses, each lasting >3 days, within 30 days prior to the first study dose.

Note: Topical, ocular, intra-articular, nasal, or inhaled corticosteroids are permitted.

  • Have a history of severe allergies or known allergic constitution.
  • Other conditions deemed unsuitable for study enrollment by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort A Dose Level 1

KDTV001:1 × 10^11 VP, IM, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

Experimental: Cohort A Dose Level 2

KDTV001: 3 × 10^11 VP, IM, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

Experimental: Cohort B Dose Level 1

KDTV001: 1 × 10^10 VP, IC, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

Experimental: Cohort B Dose Level 2

KDTV001: 3 × 10^10 VP, IC, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study
Time Frame: From enrollment to 2 years after the first dose.

Percentage of participants with AE/TRAE/SAE in FAS population

From enrollment to 2 years after the first dose.
Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical Samples
Time Frame: From enrollment to 36 weeks after the first dose.

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and HPV-18 and HPV-52 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

From enrollment to 36 weeks after the first dose.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1: HPV clearance rates after dosing;
Time Frame: From enrollment to 104 weeks after the first dose.

Incidence of Participants with no evidence of HPV-16 and HPV-18 and HPV-52 at Week 12, 24, and 36, and Week 52, 78, and 104 if the participants do not have excisional treatment. HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

From enrollment to 104 weeks after the first dose.
Phase 2: The immunogenicity of KDTV001 injection;
Time Frame: From enrollment to 52 weeks after the first dose.

Immunogenicity within 52 weeks after the first dose: cellular immune responses against E6/E7 of HPV16/18/52, including enzyme-linked immunospot (ELISPOT) assay and flow cytometry, etc.

From enrollment to 52 weeks after the first dose.
Companion biomarkers of KDTV001
Time Frame: From enrollment to 52 weeks after the first dose.
  • HPV integration;
  • Patient HLA typing;
  • p16, HPV E6/E7 and Ki67 gene expression analysis as well as immune infiltration analysis, etc. of cervical tissues;
  • Cervical gene methylation level;
  • Cell-free Human Papillomavirus DNA (cfDNA-HPV), peripheral blood immune cell subsets, and related antibody production (e.g. peripheral blood antibodies to HPV16/18/52 E6/E7 and viral vector (Ad5)).
From enrollment to 52 weeks after the first dose.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 6, 2026

Primary Completion (Estimated)

November 30, 2027

Study Completion (Estimated)

January 30, 2029

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe